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Most autoreactive B cells are normally counterse-
lected during early B cell development. To determine
whether Toll-like receptors (TLRs) regulate the re-
moval of autoreactive B lymphocytes, we tested the
reactivity of recombinant antibodies from single B
cells isolated from patients deficient for interleukin-1
receptor-associated kinase 4 (IRAK-4), myeloid dif-
ferentiation factor 88 (MyD88), andUNC-93B. Indeed,
all TLRs except TLR3 require IRAK-4 and MyD88 to
signal, andUNC-93B-deficient cells areunresponsive
to TLR3, TLR7, TLR8, and TLR9. All patients suffered
from defective central and peripheral B cell tolerance
checkpoints, resulting in the accumulation of large
numbers of autoreactive mature naive B cells in their
blood.Hence, TLR7, TLR8, andTLR9mayprevent the
recruitment of developing autoreactive B cells in
healthy donors. Paradoxically, IRAK-4-, MyD88-,
and UNC-93B-deficient patients did not display au-
toreactive antibodies in their serum or develop auto-
immune diseases, suggesting that IRAK-4, MyD88,
and UNC-93B pathway blockademay thwart autoim-
munity in humans.
INTRODUCTION
Autoreactive B cells generated by random V(D)J immunoglobulin
gene assembly are normally eliminated during their development
by both central and peripheral B cell tolerance checkpoints746 Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc.(Wardemann et al., 2003). The mechanisms that ensure human
central B cell tolerance are poorly characterized, but they are
mostly controlled by intrinsic B cell factors that sense whether
B cell receptors (BCRs) recognize autoantigens (Goodnow,
1996; Nemazee et al., 2000; Samuels et al., 2005a). In addition
to their BCRs, B cells also express germline-encoded trans-
membrane receptors called Toll-like receptors (TLRs) that were
originally described to bind microbial components but that are
also able to recognize self-antigens (Marshak-Rothstein, 2006).
Indeed, in addition to TLR1 and TLR10 complexes, whose
ligands are unknown, human B cells express TLR7 and TLR9
that bind RNA and DNA, respectively, and could play a role in
the removal of developing anti-nuclear antibody (ANA)-express-
ing B cells (Bernasconi et al., 2003; Bourke et al., 2003; Hasan
et al., 2005). The regulation of the peripheral B cell tolerance
checkpoint may involve other cell populations such as regulatory
T (Treg) cells, whose development and function may depend on
some TLR expression (Herve´ et al., 2007).
To assess whether the mechanisms that preside over the
removal of developing autoreactive B cells involve TLRs, we
analyzed B cell tolerance checkpoints in interleukin-1 receptor-
associated kinase 4 (IRAK-4)-, myeloid differentiation factor 88
(MyD88)-, and UNC-93B-deficient patients. Triggering of all
TLRs except TLR3 induces the recruitment to their intracytoplas-
mic domain of complexes formed by the adaptor protein MyD88
and IRAK-4, which mediate signaling of these receptors (Akira
and Takeda, 2004; Beutler, 2004). In addition, it has been recently
reported that the endoplasmic reticulum membrane protein
UNC-93B interacts with, and is required for, intracellular TLR3,
TLR7, TLR8, and TLR9 trafficking (Brinkmann et al., 2007;
Casrouge et al., 2006; Kim et al., 2008; Tabeta et al., 2006). Con-
sistent with the role of TLRs in innate immunity, mice lacking
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responses to bacterial challenges but were resistant to a lethal
dose of lipopolysaccharide (LPS) (Kawai et al., 1999; Suzuki
et al., 2002; Takeuchi et al., 2000). Mice with a missense mutation
in the Unc93b1 gene encoding UNC-93B also suffer from hyper-
susceptibility to infection from mouse cytomegalovirus and other
microbes (Tabeta et al., 2006). In humans, MyD88- and IRAK-
4-deficient patients are susceptible to pyogenic Gram-positive
bacterial infections because of the inability of their blood cells
to produce proinflammatory cytokines such as interleukin-1b
(IL-1b), IL-6, IL-12, tumor necrosis factor-a (TNF-a), and inter-
feron-g (IFN-g) in response to TLR and interleukin-1 receptor
(IL-1R) ligation (Haraguchi et al., 1998; Ku et al., 2007; Medvedev
et al., 2003; Picard et al., 2003). In contrast, human UNC-93B
deficiency, like TLR3 deficiency, does not compromise immunity
Figure 1. Human B Cell Activation by TLR7
and TLR9 Requires UNC-93B
(A) Human new emigrant and mature naive B cells
do not express IL-1R family members. Histograms
represent means ± standard error of the mean
(SEM) of the expression of studied genes (IL1R1,
IL18R1, IL1RL1, TLR1, TLR2, TLR3, TLR4, TLR5,
TLR6, TLR7, TLR8, TLR9, TLR10, IRAK4,
MYD88, and UNC93B1) in human new emigrant
(black bars, n = 8) or mature naive (gray bars, n = 4)
B cells assessed by gene-expression profiling with
the Affimetrix Human Genome U133 Plus 2.0
Array.
(B) UNC93B1 gene is expressed in human DCs
and, to a lesser extent, in B cells, and it is not
expressed in T cells. IL1R, TLR7, TLR9,
TLR10, IRAK4, MYD88, UNC93B1, and CD79B
gene expression was analyzed by RT-PCR
in CD19+CD10+IgM+CD27 new emigrant,
CD19+CD10IgM+CD27 mature naive, and
CD19+CD10CD27+ total memory B cells;
TCRab+CD4+CD25 T cells; CD19CD11c+HLA-
DR+ myeloid DC-enriched cells; and
CD19CD11cHLA-DR+ plasmacytoid DC-
enriched cells from healthy controls.
(C) Human B cells responses to TLR7 and TLR9
agonists depend on UNC-93B expression. Dot
plots show CD80 and CD86 expression on naive
CD19+CD27 B cells from one healthy control,
two UNC-93B-deficient patients, and one IRAK-
4-deficient patient that were either left unstimu-
lated (NS) or stimulated with F(ab0)2 anti-IgM,
CpG (TLR9 agonist), or Loxoribine (TLR7 agonist)
for 48 hr.
to most pathogens but elicits specific
defects in clearing herpes simplex viral
infections, resulting in recurrent encepha-
litis (Casrouge et al., 2006; Zhang et al.,
2007). By studying the reactivity of re-
combinant antibodies from single B cells
from one MyD88-, three IRAK-4-, and
two UNC-93B-deficient patients, we
found a high proportion of autoreactive
B cells in all patients, suggesting that
TLR pathways may prevent these B lymphocytes from entering
the mature naive B cell compartment.
RESULTS
TLR7 and TLR9 Require UNC-93B Expression
to Activate Human B Cells
IRAK-4 and MyD88 are required to mediate intracellular signaling
generated upon triggering of IL-1R family members, including
IL-1R1, IL-18R1, IL-1RL1 (also known as IL-33R), and most
TLRs except TLR3 (Akira and Takeda, 2004; Beutler, 2004).
Because the genes encoding IL-1R1, IL-18R1, and IL-1RL1 are
not expressed in new emigrant and mature naive B cells, these
molecules are not likely to play a direct role in the removal of de-
veloping autoreactive B cells (Figures 1A and 1B). In agreementImmunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc. 747
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TLR-Dependent Removal of Autoreactive B Cellswith previous reports, we found that TLR1, TLR6, TLR7, TLR10,
IRAK4, MYD88, and, to a lower degree, TLR9 genes were
expressed when we analyzed gene-expression profiles in both
new emigrant and mature naive B cells from healthy controls,
but we found that TLR2, TLR3, TLR4, TLR5, and TLR8 were not
(Figure 1A) (Bernasconi et al., 2003; Bourke et al., 2003; Hasan
et al., 2005). In addition,UNC93B1 did not seem to be expressed
in human B cells, whereasUnc93b1 is highly expressed in mouse
B cells (Figure 1A) (Tabeta et al., 2006). Because of the very low
expression, if any, of UNC93B1 transcripts detected by microar-
ray analysis of gene-expression profiles, we analyzed by reverse
transcriptase-polymerase chain reaction (RT-PCR) the expres-
sion of UNC93B1 and other TLR-related genes in new emigrant,
mature naive, and memory B cells, as well as in CD4+ T cells and
myeloid and plasmacytoid dendritic cell (DC)-enriched fractions
(Figure 1B). The CD79B gene encodes immunoglobin b (Igb),
a component of the BCR, and its expression was used as a pos-
itive control for all B cell fractions. PCR analysis confirmed micro-
array gene-expression data in that TLR7, TLR10, IRAK4,MYD88,
and, to a lesser extent, TLR9were expressed in all B cell fractions
(Figure 1B). In addition, both TLR9 and TLR10 expression was
increased in memory B cells compared to new emigrant and
mature naive B cells (Figure 1B) (Bernasconi et al., 2003; Bourke
et al., 2003). UNC93B1 transcripts were weakly detected in
human B cells, whereas they were more abundant in myeloid
and plasmacytoid DC-enriched fractions (Figure 1B).
To determine whether UNC-93B expression was required by
TLR7 and TLR9 to activate human B cells, we isolated naive
CD19+CD27 B cells from healthy controls, UNC-93B-, and
IRAK-4-deficient patients and stimulated them by TLR agonists.
Human naive B cells from healthy controls stimulated with F(ab0)2
anti-IgM, Loxoribine (TLR7 agonist), or CpG (TLR9 agonist) upre-
gulated the expression at their cell surface of costimulation
molecules CD80 and CD86 and activation markers CD25 and
CD69, as well as TLR9 and TLR10 (Figure 1C, Figures S1 and
S2 available online, and data not shown). Naive B cells from
UNC-93B- and IRAK-4-deficient patients showed responses to
F(ab0)2 anti-IgM stimulation similar to those of control B cells
(Figure 1C and Figures S1 and S2). However, UNC-93B-deficient
B cells were similar to IRAK-4-deficient B cells and failed to
upregulate CD80, CD86, CD25, CD69, TLR9, and TLR10 when
stimulated by Loxoribine or CpG (Figure 1C, Figures S1 and S2,
and data not shown) (Ku et al., 2007). We conclude that human
B cells express TLR7 and TLR9 that bind RNA- and DNA-contain-
ing antigens, respectively, and TLR10 that can associate with
TLR1 and whose ligands are unknown. In addition, human B cells
express IRAK-4 and MyD88 complexes and UNC93B1, which is
required for TLR7 and TLR9 to function.
Defective Central B Cell Tolerance Checkpoint
in IRAK-4-, MyD88-, and UNC-93B-Deficient Patients
A central B cell tolerance checkpoint removes the vast majority
of developing B cells that express highly polyreactive antibodies
in the bone marrow of healthy donors, and only a small fraction of
weakly polyreactive clones migrate to the periphery (Warde-
mann et al., 2003). To determine whether this checkpoint is af-
fected by the absence of most TLR functions, we analyzed the
reactivity of antibodies cloned from single IRAK-4-, MyD88-,
and UNC-93B-deficient CD19+CD10+IgM+CD27 new emigrant748 Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc.B cells. Antibody reactivities were then compared to those of the
corresponding B cell subpopulation from a healthy donor (HD10)
and five previously reported controls (Figure 2) (Herve´ et al.,
2007; Ng et al., 2004; Tsuiji et al., 2006; Wardemann et al.,
2003). We found that polyreactive new emigrant B cells were sig-
nificantly increased in IRAK-4-, MyD88-, and UNC-93B-deficient
patients, in which they represented 15.6%–56.1% of the clones,
whereas polyreactive new emigrant B cells represented only
5.0%–8.3% in healthy controls (Figures 2A and 2B). Using
enzyme-linked immunosorbent assay (ELISA) against human
epithelial HEp-2 cell lysate, we further demonstrated defects in
central tolerance in IRAK-4- and MyD88-deficient patients by
a high frequency of HEp-2-reactive clones (Figure 2C and
Figure S3). However, the frequency of HEp-2-reactive new emi-
grant B cells from UNC-93B-deficient patients was only slightly
increased compared to that in controls, and differences failed
to reach statistical significance (Figure 2C and Figure S3).
Thus, the removal of developing autoreactive B cells is severely
defective in the absence of IRAK-4 and MyD88 expression,
whereas the absence of UNC-93B partially affects the central
B cell tolerance checkpoint.
IRAK-4- and MyD88-Dependent Counterselection
of ANA B Cells Does Not Require UNC-93B
Central B cell tolerance is also responsible for the removal of de-
veloping B cells expressing ANAs, as illustrated by the very low
frequency of new emigrant B cells with such reactivity in healthy
controls (Figure 3A) (Wardemann et al., 2003). In contrast, IRAK-4-
and MyD88-deficient new emigrant B cells showed a high
frequency of ANA clones, which represented 34.1%, 18.5%,
and 15.4% of the new emigrant B cells in the three IRAK-4-defi-
cient patients and 7.9% in the MyD88-deficient patient (Fig-
ure 3A). ANAs expressed by IRAK-4- and MyD88-deficient
B cells could be divided into those that reacted with the con-
densed chromatin material in mitotic cells and those that did not
(Figures 3B and 3C). Chromatin-nonreactive ANAs accounted for
10.9% and 5.3% of new emigrant B cells of IRAK-4- and MyD88-
deficient patients, respectively, whereas chromatin-reactive
ANAs represented 10.7% and 2.6% of the clones (Figure 3B).
Autoreactive antibodies expressed by IRAK-4- and MyD88-
deficient B cells showed a large diversity of speckled, nucleolar,
or homogeneous anti-nuclear staining patterns (Figure 3C). Par-
adoxically, UNC-93B-deficient patients were able to properly
counterselect ANA-expressing developing B cells, thereby
suggesting that ANA B cell removal did not seem to require
UNC-93B (Figures 3A and 3B).
We further analyzed the reactivity of recombinant antibodies
from IRAK-4-, MyD88-, and UNC-93B-deficient patients and
healthy donor controls by indirect immunofluorescence on
Crithidia luciliae (Figures 3D and 3E). Antibody recognition of
the kinetoplast of C. luciliae, an organelle composed of dsDNA,
is the most specific assay for identifying anti-native dsDNA and
is routinely used for the detection of these autoantibodies in sys-
temic lupus erythematosus (SLE) patients. Using this assay, we
found that new emigrant B cells from controls and UNC-93B-
deficient patients contained no anti-dsDNA clones, confirming
the proper removal of ANA B cells in these individuals (Figure 3D).
In contrast, 2.6%–17.1% of antibodies expressed by IRAK-4-
and MyD88-deficient new emigrant B cells bound both the
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(Figures 3D and 3E and Tables S1–S14). In addition, we found
that kinetoplast-nonreactive ANAs and kinetoplast-reactive anti-
bodies display immunoglobulin heavy chain (IgH) complementar-
ity-determining regions 3 (CDR3) that contained the highest
number of positively charged amino acids (aa), such as arginines
previously shown to favor anti-DNA autoreactivity (Figure 3F)
Figure 2. Defective Central BCell Tolerance
Checkpoint in IRAK-4-, MyD88-, and UNC-
93B-Deficient Patients
(A) Antibodies from new emigrant B cells from
controls and patients were tested by ELISA for
reactivity against single-stranded DNA (ssDNA),
double-stranded DNA (dsDNA), insulin, and LPS.
Antibodies are considered polyreactive when
they recognize at least two and usually all four
antigens. Dotted lines show ED38-positive control
(Wardemann et al., 2003). Horizontal lines show
cutoff OD405 for positive reactivity. For each indi-
vidual, the frequency of polyreactive and nonpo-
lyreactive clones is summarized in pie charts,
with the number of antibodies tested indicated in
the centers.
(B and C) The frequencies of polyreactive (B) and
HEp-2-reactive (C) new emigrant B cells are com-
pared between controls and patients, and statisti-
cally significant differences are indicated. Each
diamond represents an individual, and the average
is shown with a bar.
(Herve´ et al., 2007; Radic et al., 1993;
Wardemann et al., 2003). Hence, ANA
clones, including those reacting with
chromatin, are enriched in the new emi-
grant B cell compartment when the
MyD88 and IRAK-4 signaling pathway is
defective, independently of UNC-93B.
Altered Receptor-Editing
Regulation in Developing IRAK-4-
and MyD88-Deficient B Cells
Receptor editing represents a major B cell
tolerance mechanism by which develop-
ing autoreactive B cells can be silenced,
especially those that express ANAs
(Radic and Weigert, 1995). Secondary
recombination events, first on the kappa
locus and then on the lambda locus,
provide attempts to edit autoreactive
antibodies by substituting light chains
until BCR autoreactivity is either abol-
ished or diminished to allow B cell devel-
opment to proceed (Goodnow, 1996;
Nemazee et al., 2000; Radic and Weigert,
1995). As a result, upstream variable (V)
gene usage combined with downstream
joining (J) segments is a signature for sec-
ondary recombination events. In humans,
lambda chains are more efficient at
silencing autoreactive and polyreactive
antibodies than are kappa chains, as illustrated by the lower fre-
quency of autoreactive clones in new emigrant B cells expressing
lambda chains in healthy controls (Figure 4A) (Wardemann et al.,
2004). In contrast, lambda-chain usage in IRAK-4- and MyD88-
deficient B cells did not diminish antibody autoreactivity com-
pared to that in kappa-chain-expressing clones, which suggest
defects in receptor editing in these patients (Figure 4A). InImmunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc. 749
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Requires IRAK-4 and MyD88, but Not
UNC-93B
(A) The frequency of anti-nuclear new emigrant B
cells in IRAK-4 and MyD88-deficient patients is
higher than in controls and UNC-93B-deficient
patients. Each diamond represents an individual,
and the average is shown with a bar.
(B) The frequencies of chromatin-nonreactive
and -reactive clones in IRAK-4- and MyD88-
deficient patients are higher than in controls and
UNC-93B-deficient patients. Histograms repre-
sent means ± SEM of frequencies of chromatin-
nonreactive (open bars) or chromatin-reactive
(black bars) antibodies. Statistically significant
differences between patients and controls are
indicated.
(C) ANAs from IRAK-4- and MyD88-deficient new
emigrant B cells show various patterns of anti-
nuclear staining. White arrows indicate dividing
cells that demonstrate negative (top row) or posi-
tive (bottom row) staining for the condensed
chromatin material.
(D) Increased kinetoplast-reactive antibodies in
new emigrant B cells from IRAK-4- (black bars)
and MyD88-deficient (dark gray bars) compared
to controls (open bars) and UNC-93B-deficient
patients (light gray bars). Histograms represent
means ± SEM of the proportion of kinetoplast-
reactive clones. Statistically significant differences
between patients and controls are indicated.
(E) IRAK-4- and MyD88-deficient clones express
ANAs that can recognize the kinetoplast of
C. Luciliae. White and red arrows indicate
positively stained kinetoplasts and nucleus of
C. Luciliae, respectively.
(F) Kinetoplast-reactive ANA-expressing B cells
display the highest frequency of positively
charged residues in their heavy-chain CDR3s.
New emigrant B cells from IRAK-4- and MyD88-
deficient patients were grouped into nonautoreac-
tive, autoreactive non-ANA (HEp-2-reactive and/
or polyreactive), kinetoplast-nonreactive ANA,
and kinetoplast-reactive ANA clones. Pie charts
show the proportion of heavy-chain CDR3s with
zero, one, two, and three or more positive charges.
The absolute number of clones analyzed in each B
cell fraction is indicated in the center. The average
number of positively charged residues per CDR3
is indicated below each fraction. The numbers of
positively charged residues in immunoglobulin
heavy-chain CDR3s were calculated excluding
the arginin or lysin found at position 94 in most
germline VHs.UNC-93B-deficient patients, lambda-chain usage properly
decreased autoreactivity, suggesting differences from IRAK-4-
and MyD88-deficient patients (Figure 4A). When lambda clones
were separated into nonautoreactive versus autoreactive, we
found that control and IRAK-4- and MyD88-deficient nonautor-
eactive B cells expressed a similar Jl gene usage (Figure 4B).
In contrast, IRAK-4- and MyD88-deficient autoreactive lambda
new emigrant B cells were biased toward Jl1 gene usage, which
is the most upstream of all Jls, suggesting that there was no
attempt at editing these autoreactive antibodies compared to750 Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc.autoreactive lambda clones in controls that preferentially used
the downstream Jl3 gene (Figure 4B). Despite the strong bias
toward downstream Vl gene usage in healthy controls, IRAK-4-
and MyD88-deficient autoreactive lambda clones showed an
increase in downstream Vl gene usage, whereas there was no
bias in Vl gene usage between control and patient nonautoreac-
tive lambda cells (Figure S4). Thus, downstream Vl usage
combined with highly increased upstream Jl1 usage in IRAK-4-
and MyD88-deficient autoreactive lambda new emigrant B cells
reflect a dearth of secondary recombination on this locus when
Immunity
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duction in IRAK-4- and MyD88-Deficient
Developing Autoreactive B Cells
(A) New emigrant B cells from IRAK-4- and
MyD88-deficient patients have an increased pro-
portion of autoreactive lambda clones compared
to those in controls and UNC-93B-deficient
patients. Histograms represent means ± SEM of
the proportion of k (black bars) and l (open bars)
clones that are autoreactive (polyreactive and
HEp-2-reactive combined).
(B) Autoreactive IRAK-4- and MyD88-deficient
new emigrant B cells display a lambda repertoire
suggesting defective receptor editing. Pie charts
show the proportion of the different Jl genes in
nonautoreactive and autoreactive new emigrant
B cells from healthy controls (top panel) or
IRAK-4- and MyD88-deficient patients (bottom
panel), with the number of analyzed sequences
indicated in the centers.
(C) Most ANA and all kinetoplast-reactive B cells
from IRAK-4 and MyD88-deficient patients ex-
press kappa chains. Histograms represent
means ± SEM of proportion of k (black bars) and l
(open bars) clones that are anti-nuclear (top panel)
and kinetoplast-reactive (bottom panel).
(D) The ANA expressed by IRAK-4- and MyD88-
deficient new emigrant B cells do not show any
bias toward downstream Jk3,4,5 usage compared
to the non-ANA clones. Pie charts show the pro-
portion of the different Jk genes, with the number
of analyzed sequences indicated in the centers.
(E) The ANA expressed in IRAK-4- and MyD88-de-
ficient new emigrant B cells do not show any bias
toward upstream Vk gene usage compared to the
non-ANA clones. The Vk locus is shown below,
clustered into four clans of Vk gene segments. His-
tograms represent the proportion of genes of each
Vk group for ANA (black bars) and non-ANA (open
bars) expressed by new emigrant B cells from
IRAK-4- and MyD88-deficient patients.functional IRAK-4 and MyD88 complexes could not be
expressed.
The analysis of ANA-expressing new emigrant B cells that
escaped central tolerance in IRAK-4- and MyD88-deficient pa-
tients revealed that most ANA and all kinetoplast-reactive clones
utilized kappa chains, demonstrating that editing using lambda
chains was not induced in these B cells (Figure 4C). In addition,
IRAK-4- and MyD88-deficient new emigrant B cells that express
ANAs did not show any evidence of secondary recombination
on their kappa locus (Figures 4D and 4E). There was no bias
toward downstream Jk3,4,5 gene usage in IRAK-4- and MyD88-
deficient ANA clones, nor any bias toward upstream Vk gene
usage in ANA-expressing B cells (Figures 4D and 4E). We con-
clude that kappa and lambda light-chain receptor editing is not
efficiently induced to thwart autoreactivity and silence autoreac-
tive and ANA-expressing B cell precursors in the absence of
proper IRAK-4 and MyD88 signaling.
Defective Peripheral B Cell Tolerance Checkpoint
in IRAK-4-, MyD88-, and UNC-93B-Deficient Patients
We previously demonstrated that a peripheral B cell tolerance
checkpoint further counterselects autoreactive new emigrantB cells before they enter the CD19+CD10IgM+CD27 mature
naive B cell compartment (Wardemann et al., 2003). In healthy
donors, HEp-2-reactive mature naive B lymphocytes represent
16.7%–23.3% of the clones (Figures 5A and 5B) (Wardemann
et al., 2003). In contrast, we found that the frequency of HEp-2-
reactive mature naive B cells was substantially increased and
reached 45.8%–65.4% in IRAK-4-, MyD88-, and UNC-93B-
deficient patients (Figures 5A and 5B). The mature naive B cell
compartment of all patients was also enriched in polyreactive
clones compared to healthy controls (Figure 5C and Figure S5).
In addition, the proportion of mature naive B cells expressing
ANAs reacting or not with the chromatin was slightly elevated in
IRAK-4-, MyD88-, and UNC-93B-deficient patients when com-
pared to that in healthy donors (Figures 6A and 6B). Correlating
with the presence of chromatin-reactive antibodies, kineto-
plast-reactive B cells were also identified in the mature naive
B cell compartment of IRAK-4-, MyD88-, and UNC-93B-deficient
patients (Figure 6C). Little is known about the cells and molecules
that regulate human peripheral B cell tolerance, but elevated
B cell-activating factor (BAFF) concentrations may prevent the
removal of autoreactive B cells, probably by increasing their
survival in the periphery (Herve´ et al., 2007; Lesley et al., 2004;Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc. 751
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ance Checkpoint in IRAK-4-, MyD88-, and
UNC-93B-Deficient Patients
(A) Increased frequency of HEp-2-reactive
antibodies in IRAK-4-, MyD88-, and UNC-93B-
deficient mature naive B cells. Antibodies from
mature naive B cells from one control (HD10),
three IRAK-4-deficient, one MyD88-deficient, and
two UNC-93B-deficient patients were tested in
ELISA for reactivity with HEp-2 cell lysate. Dotted
lines show ED38-positive control (Meffre et al.,
2004; Wardemann et al., 2003). Horizontal lines
show cutoff OD405 for positive reactivity. For
each individual, the frequency of HEp-2-reactive
(in black) and non-HEp-2-reactive (in white) clones
is summarized in pie charts with the number of an-
tibodies tested indicated in the centers.
(B and C) The frequency of (B) HEp-2-reactive and
(C) polyreactive (tested against ssDNA, dsDNA,
insulin, and LPS) clones in mature naive B cells
of IRAK-4-, MyD88-, and UNC-93B-deficient
patients is higher than in controls. Each diamond
represents an individual, and the average is shown
with a bar. Statistically significant differences
between patients and controls are indicated.Mackay et al., 1999; Thien et al., 2004). However, BAFF does not
account for the defective peripheral B cell tolerance checkpoint in
IRAK-4-, MyD88-, and UNC-93B-deficient patients because they
all showed normal BAFF amounts in their serum (Figure S6). We
conclude that the peripheral B cell tolerance checkpoint requires
IRAK-4, MyD88, and UNC-93B to be functional.
Human Autoreactive B Cells Fail to Secrete
Autoantibodies in the Absence of IRAK-4,
MyD88, and UNC-93B
Despite the accumulation of autoreactive B cells expressing
ANAs and polyreactive antibodies in their blood, IRAK-4-,
MyD88-, and UNC-93B-deficient patients suffer from bacterial
and viral infections, respectively, and not from autoimmune
diseases (Casanova and Abel, 2007; Casrouge et al., 2006; von
Bernuth et al., 2008). To investigate the role of IRAK-4-, MyD88-,
and UNC93-B-dependent TLRs on the activation of autoreactive
B cells through the secretion of autoreactive antibodies, we
tested nine IRAK-4-, three MyD88-, and three UNC-93B-deficient
patients for the presence of autoantibodies in their serum. We
found that these patients displayed titers of ANAs and polyreac-
tive IgG antibodies in their serum that were similar to those found
in healthy controls (Figure 7 and Figure S7). Thus, autoreactive B
cells in the blood of IRAK-4-, MyD88-, and UNC-93B-deficient
patients do not secrete ANAs and other polyreactive antibodies
when TLR signaling and functions are altered in the absence of
IRAK-4, MyD88, or UNC-93B expression.
DISCUSSION
We report herein that IRAK-4-, MyD88-, and UNC-93B-deficient
patients showed defects in the establishment of B cell tolerance.
Indeed, IRAK-4-, MyD88-, and UNC-93B-dependent pathways752 Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc.prevent the accumulation of large numbers of autoreactive
B cells in the periphery of healthy donors. Developing autoreac-
tive B cells are normally removed at two different checkpoints,
first in the bone marrow and then in the periphery. The central
B cell tolerance checkpoint seems to be mainly controlled by in-
trinsic B cell molecules that regulate BCR signaling induced by
binding to autoantigens at the immature B cell stage (Goodnow,
1996; Nemazee et al., 2000; Samuels et al., 2005a). Alterations of
BCR signaling thresholds, such as in B cells from X-linked agam-
maglobulinemia patients who carry mutations in their BTK gene,
result in defective central B cell tolerance checkpoint and in the
release of autoreactive B cells in the periphery (Ng et al., 2004). In
contrast, the peripheral B cell tolerance checkpoint seems to rely
on extrinsic molecular and cellular regulators, such as BAFF
concentration and Treg cells (Herve´ et al., 2007). How does the
absence of IRAK-4, MyD88, and UNC-93B affect mechanisms
that normally mediate these counterselection steps?
We demonstrated that signaling through IRAK-4 and MyD88
complexes plays a major role in the establishment of central B
cell tolerance in the bone marrow by counterselecting developing
autoreactive B cells, including ANA-expressing clones. Because
IL1R1, IL18R1, and IL1RL1 genes are not expressed in control B
cells, defects in the central B cell tolerance checkpoint in IRAK-4
and MyD88-deficient patients are likely to result from the inability
of TLRs to signal in the absence of functional IRAK-4 and MyD88
complexes. TLR7 and TLR9, which bind RNA- and DNA-contain-
ing antigens, respectively, were obvious candidates for the re-
moval of ANA-expressing clones. UNC-93B has been reported
to be required for these TLRs to reach endolysosomes, where
they bind ligands and initiate signaling (Kim et al., 2008; Tabeta
et al., 2006). In agreement with this observation, we found that
B cells from UNC-93B-deficient patients showed impaired
responses to TLR7 and TLR9 triggering. The apparent removal
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however, to argue against a role of TLR7 and TLR9 in this
process. Nevertheless, UNC-93B-deficient patients displayed
an increased frequency of polyreactive new emigrant B cells,
suggesting that TLR7 and TLR9 play a partial role in the establish-
ment of central B cell tolerance. In addition to TLR7 and TLR9,
human B cells express the UNC-93B-independent TLR10, either
as homodimers or as heterodimers with TLR1 (Hasan et al., 2005).
TLR10 complexes do not have any known ligands and may be
responsible for the counterselection of B cells expressing ANAs.
Alternatively, other IRAK-4 and MyD88-dependent receptors yet
to be identified may be responsible for the removal of ANA-
expressing B cell clones in the bone marrow. During their devel-
opment, B cells may encounter nuclear self-antigens in blebs
expressed at the surface of bone marrow cells dying by apoptosis
or from the enucleated material from millions of red blood cells
(Cocca et al., 2002). The binding of DNA- and RNA-containing
antigens to ANAs and other receptors may therefore generate
synergistic signals that may mediate the silencing of these
clones. Interestingly, we found that TLR10 and, to some extent,
Figure 6. Identification of ANA-Expressing Mature Naive B Cells in
IRAK-4-, MyD88-, and UNC-93B-Deficient Patients
(A) The frequency of anti-nuclear mature naive B cells in IRAK-4, MyD88-, and
UNC-93B-deficient patients is higher than in controls. Each diamond repre-
sents an individual, and the average is shown with a bar.
(B and C) Chromatin-nonreactive and -reactive (B) and kinetoplast-reactive (C)
clones are enriched in the mature naive B cell compartment of IRAK-4-,
MyD88-, and UNC-93B-deficient patients compared to those in controls. His-
tograms represent means ± SEM of proportion of (B) chromatin-nonreactive
(open bars) and chromatin-reactive (black bars) clones and (C) kinetoplast-
reactive clones.TLR9 cell-surface expression were upregulated after either
BCR triggering or BCR and TLR9 cotriggering. Thus, developing
autoreactive B cells stimulated by self-antigens express in-
creased cell-surface TLR expression that may cosignal with
BCRs and induce tolerance mechanisms. In the absence of func-
tional IRAK-4 and MyD88 expression, a lack of intracellular sig-
naling may result in altered removal of ANA clones. In agreement
with this hypothesis, we found that kappa and lambda light-chain
receptor editing was not properly induced in IRAK-4- and
MyD88-deficient B cell precursors, which resulted in the appear-
ance of a population of kappa-expressing anti-nuclear B cells.
Hence, the TLR and BCR coengagement paradigm may apply
not only to B cell activation and proliferation, but also to the
selection of developing B cells in the bone marrow.
All IRAK-4-, MyD88-, and UNC-93B-deficient patients dis-
played a similar defective peripheral B cell tolerance checkpoint,
resulting in the accumulation of large numbers of autoreactive B
cells in the blood of these patients. Because TLR3, TLR7, TLR8,
and TLR9 are the only receptors that depend on UNC-93B to
function, and because TLR3 signaling does not require IRAK-4
and MyD88 complexes, it is likely that TLR7, TLR8, and TLR9
are responsible for the removal of autoreactive B cells in the
periphery. Little is known about the cells and molecules that reg-
ulate human peripheral B cell tolerance or about how TLR7,
TLR8, and TLR9 could be involved. In agreement with findings
from mouse models, our recent data suggest that elevated
BAFF concentrations may prevent the removal of autoreactive
B cells, probably by increasing their survival in the periphery
(Herve´ et al., 2007; Lesley et al., 2004; Mackay et al., 1999; Thien
et al., 2004). However, BAFF does not account for the defective
peripheral B cell tolerance checkpoint in IRAK-4-, MyD88-, and
UNC-93B-deficient patients because they all showed normal
BAFF amounts in their serum. In addition to BAFF, Treg cells
may also control the elimination of autoreactive B cells in the
periphery (Herve´ et al., 2007). Indeed, the decreased numbers
of Treg cells in CD40L- and major histocompatibility complex
Figure 7. Lack of Serum ANAs in IRAK-4-, MyD88-, and UNC-93B-
Deficient Patients
The presence of IgG ANAs was assessed by ELISA in the serum of healthy con-
trols and IRAK-4-, MyD88-, and UNC-93B-deficient patients. Each diamond
represents an individual. Dashed lines indicate threshold between negative,
low-positive, and positive individuals for serum IgG ANAs.Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc. 753
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toreactive B cells in the mature naive B cell compartment, but not
in the new emigrant B cell compartment, suggest that these
T cells may mediate peripheral B cell tolerance (Herve´ et al.,
2007). A similar hypothesis was previously proposed with trans-
genic mouse models, in which CD4+ T cells and the receptor-
ligand pairs CD40-CD40L and Fas-FasL have been shown to
play an important role in removing tolerant hen-egg-lysozyme-
binding B cells (Rathmell et al., 1995; Rathmell et al., 1996). A
direct involvement of TLR7, TLR8, and TLR9 on human Treg
cell development and functions is difficult to assess because
TLR stimulation can either increase or decrease the regulatory
properties of these T cells (Conroy et al., 2008). However, the
roles of TLR7 and TLR9 on DCs have been well characterized,
especially in plasmacytoid DCs (pDCs), which mostly express
these TLRs (Kadowaki et al., 2001), Interestingly, pDCs have
been reported to play an important role in the development of
Treg cells when primed by TLR agonists (Ito et al., 2007; Mose-
man et al., 2004; Ouabed et al., 2008; Watanabe et al., 2005). We
would therefore like to propose that in the absence of TLR7 and
TLR9 signaling in IRAK-4, MyD88-, and UNC-93B-deficient
patients, pDCs may not be able to induce the development of
Treg cells specific for a whole set of self-antigens. Moreover,
DC-Treg cell interactions may also be affected because IRAK-
4-deficient DCs show lower CD40, CD80, and CD86 expression
after stimulation by a TLR agonist (Ku et al., 2007). Altogether,
a failure to properly educate Treg cells may generate an incom-
plete Treg cell repertoire unable to counterselect some autor-
eactive B cells in the periphery. In addition, the inability of
IRAK-4-, MyD88-, and UNC-93B-deficient monocytes and DCs
to properly secrete cytokines such as IFNs and TNF-a in
response to TLR stimulation may also impact on the peripheral
B cell tolerance checkpoint (Ku et al., 2007). In conclusion,
altered Treg cell and/or DC functions in IRAK-4-, MyD88-, and
UNC-93B-deficient patients may lead to the defective peripheral
B cell tolerance checkpoint observed in these patients.
Despite the large number of peripheral autoreactive B cells in
IRAK-4-, MyD88-, and UNC-93B-deficient patients, these indi-
viduals suffer from bacterial or viral infections and not from auto-
immune diseases. We found that these patients did not display
ANAs or show any increase in polyreactive antibodies in their
serum. Thus, the autoreactive and polyreactive B cells in their
blood are not activated and do not secrete these antibodies
when TLR signaling is altered. In agreement with this observation,
many reports using mouse models demonstrated that TLR7 and
TLR9 play an essential role in activating autoreactive B cells by
transducing costimulatory signals to BCRs that bind DNA- and
RNA-containing immune complexes (Baccala et al., 2007;
Marshak-Rothstein, 2006). In addition, mouse models further
support a role for MyD88 and TLR7 in the development of autoim-
munity (Berland et al., 2006; Christensen et al., 2006; Ehlers et al.,
2006; Pisitkun et al., 2006). The TLR7 pathway was therefore
proposed to represent a therapeutic target in diseases like SLE
(Berland et al., 2006; Christensen et al., 2006; Pisitkun et al.,
2006). Our data show that IRAK-4-, MyD88-, and UNC-93B-
deficient patients present frequencies of autoreactive mature
naive B cells similar to those from patients suffering from rheuma-
toid arthritis and SLE (Samuels et al., 2005b; Yurasov et al., 2005).
However, in contrast to these patients, IRAK-4-, MyD88-, and754 Immunity 29, 746–757, November 14, 2008 ª2008 Elsevier Inc.UNC-93B-deficient patients did not develop autoimmune
diseases, further suggesting that blocking TLR pathways in
humans may thwart the development of autoimmunity.
In conclusion, the accumulation of autoreactive B cells in the
mature naive B cell compartment of IRAK-4-, MyD88-, and
UNC-93B-deficient patients suggests that pathways mediated
by IRAK-4, MyD88, and UNC-93B play an important role in coun-
terselecting developing autoreactive B cells and preventing
their maturation into long-lived mature naive B cells in healthy
individuals.
EXPERIMENTAL PROCEDURES
Patients and Healthy Donor Controls
The four IRAK-4-deficient patients belong to four unrelated families. They all
suffered from recurrent pyogenic bacterial infections but were healthy when
blood samples were obtained. They had no history of related autoimmune dis-
orders. Patient 1 is a 23-year-old woman who was born from unrelated parents
(Kuhns et al., 1997; Medvedev et al., 2003). She suffers from two different mu-
tations on her IRAK4 gene alleles. The first is a cytidine-to-thymidine mutation
at nucleotide 877, resulting in a stop codon instead of the wild-type glutamine
in the IRAK-4 kinase domain (Medvedev et al., 2003). The second mutation is
a two-nucleotide deletion at nucleotides 620–621 that results in a frameshift
creating a stop codon 36–39 nucleotides downstream, also in the kinase
domain of IRAK-4 (Medvedev et al., 2003). Patient 2 is a 10-year-old girl
who was born to consanguineous parents (Day et al., 2004; Haraguchi et al.,
1998). She displays the same cytidine-to-thymidine mutation from patient
1 on both of her IRAK4 gene alleles (Picard et al., 2003). Patient 3 is an
8-year-old boy who suffers from a homozygous deletion of the noncoding
exon 1 of the IRAK4 gene reported as P15 in Ku et al., 2007. Patient 4 is
a 16-month-old boy. He suffers from two different mutations on his IRAK4
gene alleles. The first mutation is the same cytidine-to-thymidine mutation
displayed by patients 1 and 2. The second mutation is a deletion in exon 5.
The MyD88-deficient patient is a 2-year-old Turkish girl born from nonconsan-
guineous parents (von Bernuth et al., 2008). This patient displays compound
heterozygous mutations in MYD88: L93P in exon 1 that encodes the death do-
main of MyD88 and R196C in exon 3 that is contained in the Toll-IL-1 receptor
(TIR) domain of the protein (von Bernuth et al., 2008). Both UNC-93B-deficient
patients were teenagers born from first-cousin parents (Casrouge et al., 2006).
UNC-93B-deficient patient 1 is homozygous for a four-nucleotide deletion at
position 1034–1037 in exon 8, whereas patient 2 is homozygous for a single-
nucleotide substitution in exon 6 that prevents the splicing of this exon
(Casrouge et al., 2006). Healthy donors include a 36-year-old Caucasian
male (HD10) and five previously reported controls (Herve´ et al., 2007; Ng
et al., 2004; Tsuiji et al., 2006; Wardemann et al., 2003). Overall, the ages of
healthy controls range from 5 years old to 37 years old and match the diverse
ages of the patients enrolled in the study (Herve´ et al., 2007; Ng et al., 2004;
Tsuiji et al., 2006; Wardemann et al., 2003). All samples were collected after
patients signed informed consent in accordance with protocols reviewed by
the institutional review board. Informed consent as approved by the institu-
tional review board was obtained from the custodians of subjects younger
than 18 years, and assent was signed by children and adolescents older
than 8 years as well.
Cell Sorting
Peripheral B cells were purified from the blood of patients and control donors
by negative selection with RosetteSep procedure (StemCell Technologies).
Enriched B cells were stained with fluorescein isothiocyanate (FITC) anti-
human CD27, phycoerythrin (PE) anti-human CD10, anti-human IgM biotin,
and allophycocyanin (APC) anti-human CD19. Biotinylated antibodies were
revealed with streptavidin-PECy7. Single CD19+CD10+IgM+CD27 new
emigrant and CD19+CD10IgM+CD27 peripheral mature naive B cells from
patients and control donors were sorted on a FACSVantage (Becton Deckin-
son) into 96-well PCR plates containing 4 ml of lysis solution (0.5 3 PBS
containing 10 mM DTT, 8 U RNAsin [Promega], and 0.4 U 50-30 RNase Inhibitor
[Eppendorf]) and immediately frozen on dry ice. All samples were stored at
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sorted with antibodies described above and anti-TCRab-FITC, anti-CD25-
PE, anti-CD4-PECy7, anti-CD11c-PE, and anti-HLA-DR-APC. All antibodies
were purchased from PharMingen, Becton Dickinson.
B Cell Activation
Naive B cells were enriched with the Human Naive B Cell Isolation Kit II (Milte-
nyi). CD19+CD27 naive B cells from control donors and patients were plated
at 150,000–200,000 cells per well in a 96-well plate in RPMI 10% serum and
20 mg/mL polyclonal F(ab)02 rabbit anti-human IgM (Jackson Immunore-
search), 1 mg/mL CpG (Invivogen), or 0.5 mM Loxoribine (Invivogen) for 48 hr.
Flow-cytometry analysiswas performed with anti-CD86-FITC, anti-CD25-FITC,
anti-CD10-APC (Biolegend), anti-CD80-PE, anti-CD69-PE, anti-CD19-PECy7
(PharMingen, Beckton Dickinson), anti-TLR10-FITC, and anti-TLR-9-PE
(Imgenex).
RNA and RT-PCRs
Total RNA was extracted from 105 purified cells with Absolutely RNA microprep
kit (Stratagene). RNA was reverse transcribed in 20 ml with Superscript II
(GIBCO BRL). For RT-PCR reactions, 2 ml of cDNA was amplified for 32 cycles
of 30 s at 94C, 30 s at 60C (TLR7) or at 63C (IL1R, TLR9, TLR10, IRAK4,
MYD88, UNC93B1, and CD79b), and 30 s at 72C, with a final 7 min extension
at 72C with Taq DNA polymerase (Roche) and the following primers: IL1R1
sense 50CATAGAGGGAACTATACTTGTCATG30; IL1R1 antisense 50CATTAGC
TGGGCTCACAATCACAG30; TLR7 sense 50TTTGGAAGAAGACTAAAAATGGT
G30; TLR7 antisense 50GAACATCCAGAGTGACATCACAG30; TLR9 sense 50CC
GCCAGACCCTCTGGAGAAG30; TLR9 antisense 50ACTTCAGGAACAGCCAG
TTGCAG30; TLR10 sense 50CCCAAGAACAACTCAAGAGAAATG30; TLR10
antisense 50TGCTTTTGCCAGGGTCAAAGTAG30; IRAK4 sense 50CATATGTG
CGCTGCCTCAATGTTG30; IRAK4 antisense 50CCAGTCAAACAGTAATTCAGA
AGTG30; MYD88 sense 50GACGACGTGCTGCTGGAGCTG30; MYD88 anti-
sense 50GATGAAGGCATCGAAACGCTCAG30; UNC93B1 sense 50GCGAGGT
GAAGTATGGCAACATG30; and UNC93B1 antisense 50GGCGTAGATGCCCA
CAGCGAG30. CD79b primers were previously described (Meffre et al., 1998).
RT-PCR products were analyzed on 2% agarose gels.
Microarray Analysis of Gene-Expression Profiles
RNA was extracted from 105–3.105 batch-sorted new emigrant and mature
naive B cells isolated from donors with the Absolutely RNA microprep kit (Stra-
tagene). 100–200 ng of RNA was obtained per sample, and the quality of the
purified RNA was assessed by the Bioanalyzer from Agilent. With the Ovation
biotin system kit from Nugen, 30–50 ng of RNA was amplified and labeled for
producing cDNA. Labeled cDNA was hybridized on chips containing the whole
human genome (Human Genome U133 2.0 from Affymetrix).
cDNA, RT-PCR, and Antibody Production and Purification
RNA from single cells was reverse transcribed in the original 96-well plate in
12.5 ml reactions containing 100 U of Superscript II RT (GIBCO BRL) for
45 min at 37C. RT-PCR reactions, primer sequences, cloning strategy, ex-
pression vectors, and antibody expression and purification were as described
(Meffre et al., 2004; Wardemann et al., 2003). Immunoglobulin sequences were
analyzed by Ig BLAST comparison with GenBank. Heavy-chain CDR3 was de-
fined as the interval between the conserved cysteine at position 92 in the VH
framework 3 and the conserved tryptophan at position 103 in JH segments.
ELISAs and Immunofluorescence Assays
Antibody concentrations, reactivity against specific antigens, and indirect
immunofluorescence were as described (Meffre et al., 2004; Wardemann
et al., 2003). Highly polyreactive ED38 was used as positive control in
HEp-2-reactivity and polyreactivity ELISAs (Meffre et al., 2004; Wardemann
et al., 2003). Antibodies were considered polyreactive when they recognized
at least two and usually all of the four analyzed antigens, which include ssDNA,
dsDNA, insulin, and LPS. Serum ANA titers of total IgG from patients and
healthy controls were determined with INOVA QUANTA Lite ANA ELISA
according to the manufacturer’s instructions.
For indirect immunofluorescence assays, HEp-2 cell coated slides (Bion En-
terprises) and Crithidia luciliae coated slides (Antibodies Inc.) were incubated
in a moist chamber at room temperature with purified recombinant antibodiesat 50–100 mg/mL and 100–200 mg/mL, respectively. FITC-conjugated goat
anti-human IgG was used as detection reagent.
Statistics
Differences were analyzed for statistical significance with unpaired Student’s
t tests with SigmaPlot software (Systat). A p value of less than 0.05 was
considered significant.
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